Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05109910

The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical Prostatectomy

Prospective Randomized Controlled Trial To Evaluate The Prognostic Role of Lymph Node Dissection In Men With Prostate Cancer Treated With Radical Prostatectomy

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
284 (estimated)
Sponsor
The Netherlands Cancer Institute · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

An extended pelvic lymph node dissection (ePLND) is the most accurate staging method to assess the presence of lymph node metastases in prostate cancer (PCa) patients. The therapeutic value, however remains unclear. Prospective randomized trials to address this void are lacking. Since in intermediate and a proportion of high risk PCa the risk of nodal metastases is generally below 25%, the vast majority of men undergo a procedure that has no oncological benefit, but is not without toxicity. Therefore, the investigators aim to compare the oncologic outcomes of intermediate- and high-risk PCa patients with an estimated risk of lymph node invasion of 5-20% undergoing a radical prostatectomy (RP) with or without an ePLND.

Detailed description

The role of an extended pelvic lymph node dissection (ePLND) in patients undergoing radical prostatectomy (RP) remains controversial. An ePLND is the most accurate staging method to assess the presence of lymph node metastases. Lymph node involvement is associated with a significantly worse prognosis and may require immediate or delayed adjuvant therapy. However, an ePLND is associated with an increased risk of complications such as lymphoceles, thromboses and lymphedema, and prolongs surgery and patient recovery. Thus, the diagnostic advantage of PLND should be weighed against the potential morbidity. The therapeutic value of an ePLND remains especially unclear in PCa patients with an estimated risk of lymph node invasion (LNI) ≤ 20%, where only a minority of patients will have nodes harbouring metastases. Prospective trials to address this issue are still lacking.

Conditions

Interventions

TypeNameDescription
PROCEDUREPelvic lymph node dissectionBilateral extended pelvic lymph node dissection

Timeline

Start date
2021-11-17
Primary completion
2024-11-01
Completion
2027-11-01
First posted
2021-11-05
Last updated
2021-11-18

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT05109910. Inclusion in this directory is not an endorsement.